02769nas a2200493   4500000000100000008004100001260001300042653001000055653002600065653002400091653002300115653001100138653002500149653002100174653003800195653001100233653001600244653001100260653002100271653001200292653000900304653002500313100001500338700001600353700001500369700001300384700001400397700001300411700001500424700001700439700001500456700001500471700002200486700001100508700001300519700001600532245011200548856004800660300001100708490001600719050001800735520150800753022001402261       2012                            d  c2012 Dec10aAdult10aAntibodies, Bacterial10aAntigens, Bacterial10aBacterial Proteins10aBrazil10aCase-Control Studies10aEndemic Diseases10aEnzyme-Linked Immunosorbent Assay10aFemale10aGlycolipids10aHumans10aImmunoglobulin M10aleprosy10aMale10aMycobacterium leprae1 aHungria EM1 aOliveira RM1 aSouza ALOM1 aCosta MB1 aSouza VNB1 aSilva EA1 aMoreno FRV1 aNogueira MES1 aCosta MRSN1 aSilva SMUR1 aBührer-Sékula S1 aReed S1 aDuthie M1 aStefani MMA00aSeroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil.  uhttp://www.scielo.br/pdf/mioc/v107s1/17.pdf  a104-110 v107 Suppl 1  aHUNGARIA 20123 a<p>New Mycobacterium leprae protein antigens can contribute to improved serologic tests for leprosy diagnosis/classification and multidrug therapy (MDT) monitoring. This study describes seroreactivity to M. leprae proteins among participants from three highly endemic leprosy areas in Brazil: central-western Goiânia/Goiás (GO) (n = 225), Rondonópolis/Mato Grosso (MT) (n = 764) and northern Prata Village/Pará (PA) (n = 93). ELISA was performed to detect IgG to proteins (92f, 46f, leprosy IDRI diagnostic-1, ML0405, ML1213) and IgM to phenolic glycolipid-I (PGL-I). Multibacillary (MB) leprosy had positive rates for PGL-I that were similar to those for proteins; however, some anti-PGL-I-negative subjects were positive for proteins, suggesting that adding protein antigen to PGL-I can enhance the sensitivity of MB leprosy detection. In MT, different degrees of seroreactivity were observed and ranked for MB, former patients after MDT, paucibacillary (PB) leprosy, household contact (HHC) and endemic control (EC) groups. The seroreactivity of PB patients was low in GO and MT. HHCs from different endemic sites had similar IgG antibody responses to proteins. 46f and 92f were not recognised by most tuberculosis patients, ECs or HHCs within GO, an area with high BCG vaccination coverage. Low positivity in EC and HHC was observed in PA and MT. Our results provide evidence for the development of an improved serologic test that could be widely applicable for MB leprosy testing in Brazil.</p>  a1678-8060